Skip to Content

Advanced Search

Login
|
Create a Profile
|
Quick Order
|
(0 items)
|
USA

Select another country:

|
1.800.638.6597

MIA PaCa-2 (ATCC^® CRM-CRL-1420^™)

Organism: Homo sapiens, human / Cell Type: epithelial cell (KRAS CRM) / Tissue: pancreas / Disease: carcinoma

MIA PaCa-2 ATCC^® CRM-CRL-1420^™

frozen

For-Profit: $714.00 Non-Profit: $606.90

Qty:

Recommended for this product

Permits and Restrictions	View Permits
Organism	Homo sapiens, human
Tissue	pancreas
Cell Type	epithelial cell (KRAS CRM)
Product Format	frozen
Morphology	attached epithelial with floating rounded cells
Culture Properties	adherent, single cells and loosely attached clusters
Biosafety Level	1 Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease	carcinoma
Age	65 years
Gender	Male
Ethnicity	Caucasian
Applications	For use in testing and calibration in ISO 17025 accredited laboratories, to challenge assay performance, validate or compare test methods, and to establish sensitivity, linearity and specificity during assay validation or implementation. ISO Guide 34:2009
Intended Use	Certified Reference Material produced under an ISO Guide 34:2009 accredited process.
Storage Conditions	liquid nitrogen vapor phase

Karyotype	This is a hypotriploid human cell line. The modal chromosome number is 61. Sixteen to 20 marker chromosomes are commonly found in a cell. A few normal chromosomes are absent.
Derivation	The MIA PaCa-2 cell line was established by A. Yunis, et al. in 1975 from tumor tissue of the pancreas obtained from a 65-year-old Caucasian male. Hybridomas have been made against the CSF-I produced by this line ATCC HB-8207 (F1A3-23) and ATCC HB-8208 (F18 AF1).
Clinical Data	65 years Caucasian male
Genes Expressed	human colony stimulating factor, subclass I (CSF-I); plasminogen activator
Cellular Products	human colony stimulating factor, subclass I (CSF-I); plasminogen activator
Comments	Certificates of Analysis are available electronically at www.atcc.org, or by hardcopy upon request. Certified Reference Material produced under an ISO Guide 34:2009 accredited process. Item has been tested for KRAS mutation (p.G12C c.34G>T) The established cell line reportedly has a doubling time of about 40 hours and a colony-forming efficiency in soft agar of approximately 19%. The line is sensitive to asparaginase.

Complete Growth Medium	The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%; horse serum to a final concentration of 2.5%.
Subculturing	Protocol: Remove medium, and rinse with 0.25% trypsin, 0.53 mM EDTA solution. Remove the solution and add an additional 1 to 2 mL of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended Medium Renewal: 2 to 3 times per week
Cryopreservation	Freeze Medium: Complete growth medium 95%; DMSO, 5% Storage Temperature: Liquid nitrogen vapor phase
Culture Conditions	Temperature: 37°C

STR Profile	Amelogenin: X CSF1PO: 10 D13S317: 12,13 D16S539: 10,13 D5S818: 12,13 D7S820: 12,13 THO1: 9,10 TPOX: 9 vWA: 15
Isoenzymes	G6PD, B

Name of Depositor	A Yunis
Deposited As	Homo sapiens
Year of Origin	1975
References	Wu M, et al. Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells. Biochemistry 16: 1908-1913, 1977. PubMed: 15590 Fountzilas G, et al. Comparative effects of selected drug combinations on the growth of a human pancreatic carcinoma cell line (MIA PaCa-2). J. Natl. Cancer Inst. 76: 37-43, 1986. PubMed: 3455740 Robertson JF, et al. Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Int. J. Cancer 63: 69-75, 1995. PubMed: 7558455 Yunis AA, et al. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int. J. Cancer 19: 128-135, 1977. PubMed: 832918

Permits	These permits may be required for shipping this product: Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation	Product Sheet Certificate of Analysis SDS
FAQ's	Agreement to transfer to a CRO Date Updated: 1/2/2013
References	Wu M, et al. Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells. Biochemistry 16: 1908-1913, 1977. PubMed: 15590 Fountzilas G, et al. Comparative effects of selected drug combinations on the growth of a human pancreatic carcinoma cell line (MIA PaCa-2). J. Natl. Cancer Inst. 76: 37-43, 1986. PubMed: 3455740 Robertson JF, et al. Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Int. J. Cancer 63: 69-75, 1995. PubMed: 7558455 Yunis AA, et al. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int. J. Cancer 19: 128-135, 1977. PubMed: 832918